Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PFSB Plans Radical Review of PMDA to Speed Drug Approval
October 23, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 23, 2006
- REGULATORY NEWS IN BRIEF -1-
October 23, 2006
- SEMINAR
October 23, 2006
- Tohoku Univ. Researchers Apply for Patent for Vascular Function Monitoring System
October 23, 2006
- SELF-MEDICATION NEWS IN BRIEF
October 23, 2006
- JPA to Launch Data Sheet Database in Early December
October 23, 2006
- SURVEY 2 articles
October 23, 2006
- Shionogi, Hokkaido Univ. Jointly Create Drug Discovery Center
October 23, 2006
- New PM to Promote Innovation in Pharmaceutical Field
October 16, 2006
- PMDA to Continue to Strengthen Its Review Teams
October 16, 2006
- New EAD Director to Focus on Strengthening Drug Industry's Int'l Competitiveness
October 16, 2006
- ADR Manuals for 120 Diseases to Be Prepared by FY2008: New SD Director
October 16, 2006
- REGULATORY NEWS IN BRIEF
October 16, 2006
- Kyowa Hakko Licenses Original Anticancer Agent to Keryx
October 16, 2006
- Takeda Announces Agreement for Novel Analgesic XEN401
October 16, 2006
- 65th Annual Meeting of Japanese Cancer Association (2)－1
October 16, 2006
- 65th Annual Meeting of Japanese Cancer Association (2)－2
October 16, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 16, 2006
- R&D NEWS IN BRIEF
October 16, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…